169 related articles for article (PubMed ID: 25790904)
21. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
Buckley PF
Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
[TBL] [Abstract][Full Text] [Related]
22. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
[TBL] [Abstract][Full Text] [Related]
23. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories.
Levine SZ; Leucht S
Biol Psychiatry; 2010 Jul; 68(1):86-92. PubMed ID: 20227681
[TBL] [Abstract][Full Text] [Related]
24. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
25. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data.
Rabinowitz J; Davidov O
Schizophr Bull; 2008 Mar; 34(2):286-91. PubMed ID: 18212325
[TBL] [Abstract][Full Text] [Related]
26. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
[TBL] [Abstract][Full Text] [Related]
27. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features.
Rabinowitz J; Levine SZ; Barkai O; Davidov O
Schizophr Bull; 2009 Jul; 35(4):775-88. PubMed ID: 18303093
[TBL] [Abstract][Full Text] [Related]
28. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
Citrome L; Meng X; Hochfeld M
Schizophr Res; 2011 Sep; 131(1-3):75-81. PubMed ID: 21700430
[TBL] [Abstract][Full Text] [Related]
30. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial.
Abbasi SH; Behpournia H; Ghoreshi A; Salehi B; Raznahan M; Rezazadeh SA; Rezaei F; Akhondzadeh S
Schizophr Res; 2010 Feb; 116(2-3):101-6. PubMed ID: 19959338
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
[TBL] [Abstract][Full Text] [Related]
32. Attaining and sustaining remission of predominant negative symptoms.
Levine SZ; Leucht S
Schizophr Res; 2013 Jan; 143(1):60-4. PubMed ID: 23218563
[TBL] [Abstract][Full Text] [Related]
33. The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia.
Spineli LM; Leucht S; Cipriani A; Higgins JP; Salanti G
Eur Neuropsychopharmacol; 2013 Sep; 23(9):1010-6. PubMed ID: 23639793
[TBL] [Abstract][Full Text] [Related]
34. Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials.
Rabinowitz J; Werbeloff N; Caers I; Mandel FS; Stauffer V; Ménard F; Kinon BJ; Kapur S
J Clin Psychiatry; 2014 Apr; 75(4):e308-16. PubMed ID: 24813414
[TBL] [Abstract][Full Text] [Related]
35. The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues: An Update From the US Food and Drug Administration.
Gopalakrishnan M; Zhu H; Farchione TR; Mathis M; Mehta M; Uppoor R; Younis I
J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32141721
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of Dropout Rates in Placebo-Controlled Randomized Clinical Trials of Atypical Antipsychotics Assessed by PANSS.
Matsusaki A; Kaneko M; Narukawa M
Clin Drug Investig; 2019 Oct; 39(10):917-926. PubMed ID: 31250403
[TBL] [Abstract][Full Text] [Related]
37. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?
Leucht S; Engel RR; Bäuml J; Davis JM
Schizophr Bull; 2007 Jan; 33(1):183-91. PubMed ID: 16905632
[TBL] [Abstract][Full Text] [Related]
38. Development of a placebo effect model combined with a dropout model for bipolar disorder.
Sun W; Laughren TP; Zhu H; Hochhaus G; Wang Y
J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):359-68. PubMed ID: 23456101
[TBL] [Abstract][Full Text] [Related]
39. Interpreting treatment trials in schizophrenia patients: lessons learned from EUFEST.
Fleischhacker WW; Derks E; Kahn RS
Schizophr Res; 2012 Jun; 138(1):39-40. PubMed ID: 22542244
[TBL] [Abstract][Full Text] [Related]
40. 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response.
Leucht S; Chaimani A; Leucht C; Huhn M; Mavridis D; Helfer B; Samara M; Cipriani A; Geddes JR; Salanti G; Davis JM
Schizophr Res; 2018 Nov; 201():315-323. PubMed ID: 29804928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
